-
1
-
-
84969664011
-
Alzheimer's disease: potential preventive, non-invasive, intervention strategies in lowering the risk of cognitive decline — a review study
-
[1] Klimova, B., Kuca, K., Alzheimer's disease: potential preventive, non-invasive, intervention strategies in lowering the risk of cognitive decline — a review study. J. Appl. Biomed. 13:4 (2015), 257–261.
-
(2015)
J. Appl. Biomed.
, vol.13
, Issue.4
, pp. 257-261
-
-
Klimova, B.1
Kuca, K.2
-
2
-
-
84925880097
-
2015 — Alzheimer's disease facts and figures
-
[2] Alzheimer's, A., 2015 — Alzheimer's disease facts and figures. Alzheimer's Dementia, 11(3), 2015, 332.
-
(2015)
Alzheimer's Dementia
, vol.11
, Issue.3
, pp. 332
-
-
Alzheimer's, A.1
-
3
-
-
79956098248
-
Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease
-
[3] Sperling, R.A., Aisen, P.S., Beckett, L.A., et al. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimer's Dementia 7:3 (2011), 280–292.
-
(2011)
Alzheimer's Dementia
, vol.7
, Issue.3
, pp. 280-292
-
-
Sperling, R.A.1
Aisen, P.S.2
Beckett, L.A.3
-
4
-
-
84875250937
-
Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study
-
[4] Villemagne, V.L., Burnham, S., Bourgeat, P., et al. Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study. Lancet Neurol. 12:4 (2013), 357–367.
-
(2013)
Lancet Neurol.
, vol.12
, Issue.4
, pp. 357-367
-
-
Villemagne, V.L.1
Burnham, S.2
Bourgeat, P.3
-
5
-
-
84869126018
-
Brain imaging and fluid biomarker analysis in young adults at genetic risk for autosomal dominant Alzheimer's disease in the presenilin 1 E280A kindred: a case-control study
-
[5] Reiman, E.M., Quiroz, Y.T., Fleisher, A.S., et al. Brain imaging and fluid biomarker analysis in young adults at genetic risk for autosomal dominant Alzheimer's disease in the presenilin 1 E280A kindred: a case-control study. Lancet Neurol. 11:12 (2012), 1048–1056.
-
(2012)
Lancet Neurol.
, vol.11
, Issue.12
, pp. 1048-1056
-
-
Reiman, E.M.1
Quiroz, Y.T.2
Fleisher, A.S.3
-
6
-
-
84871651931
-
Genetics of Alzheimer's disease
-
[6] Vilatela, M.E.A., López-López, M., Yescas-Gómez, P., Genetics of Alzheimer's disease. Arch. Med. Res. 43:8 (2012), 622–631.
-
(2012)
Arch. Med. Res.
, vol.43
, Issue.8
, pp. 622-631
-
-
Vilatela, M.E.A.1
López-López, M.2
Yescas-Gómez, P.3
-
7
-
-
84876891556
-
Benefits of combined cholinesterase inhibitor and memantine treatment in moderate–severe Alzheimer's disease
-
[7] Gauthier, S., Molinuevo, J.L., Benefits of combined cholinesterase inhibitor and memantine treatment in moderate–severe Alzheimer's disease. Alzheimer's Dementia 9:3 (2013), 326–331.
-
(2013)
Alzheimer's Dementia
, vol.9
, Issue.3
, pp. 326-331
-
-
Gauthier, S.1
Molinuevo, J.L.2
-
8
-
-
3042833662
-
Alzheimer's disease pathogenesis and therapeutic interventions
-
[8] Parihar, M., Hemnani, T., Alzheimer's disease pathogenesis and therapeutic interventions. J. Clin. Neurosci. 11:5 (2004), 456–467.
-
(2004)
J. Clin. Neurosci.
, vol.11
, Issue.5
, pp. 456-467
-
-
Parihar, M.1
Hemnani, T.2
-
9
-
-
67651180986
-
The amyloid hypothesis for Alzheimer's disease: a critical reappraisal
-
[9] Hardy, J., The amyloid hypothesis for Alzheimer's disease: a critical reappraisal. J. Neurochem. 110:4 (2009), 1129–1134.
-
(2009)
J. Neurochem.
, vol.110
, Issue.4
, pp. 1129-1134
-
-
Hardy, J.1
-
10
-
-
79959886270
-
Amyloid precursor protein processing and Alzheimer's disease
-
[10] O'Brien, R.J., Wong, P.C., Amyloid precursor protein processing and Alzheimer's disease. Annu. Rev. Neurosci. 34 (2011), 185–204.
-
(2011)
Annu. Rev. Neurosci.
, vol.34
, pp. 185-204
-
-
O'Brien, R.J.1
Wong, P.C.2
-
11
-
-
0004681572
-
Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloidogenic derivative
-
[11] Glenner, G., Wong, C., Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloidogenic derivative. Science 255 (1984), 728–730.
-
(1984)
Science
, vol.255
, pp. 728-730
-
-
Glenner, G.1
Wong, C.2
-
12
-
-
77953518555
-
Alzheimer's disease: clinical trials and drug development
-
[12] Mangialasche, F., Solomon, A., Winblad, B., et al. Alzheimer's disease: clinical trials and drug development. Lancet Neurol. 9:7 (2010), 702–716.
-
(2010)
Lancet Neurol.
, vol.9
, Issue.7
, pp. 702-716
-
-
Mangialasche, F.1
Solomon, A.2
Winblad, B.3
-
13
-
-
79955738773
-
The history of the cholinergic hypothesis
-
[13] Contestabile, A., The history of the cholinergic hypothesis. Behav. Brain Res. 221:2 (2011), 334–340.
-
(2011)
Behav. Brain Res.
, vol.221
, Issue.2
, pp. 334-340
-
-
Contestabile, A.1
-
14
-
-
65249104851
-
Molecular mechanisms of excitotoxicity and their relevance to pathogenesis of neurodegenerative diseases
-
[14] Dong, X.-X., Wang, Y., Z-H, Q., Molecular mechanisms of excitotoxicity and their relevance to pathogenesis of neurodegenerative diseases. Acta Pharmacol. Sin. 30:4 (2009), 379–387.
-
(2009)
Acta Pharmacol. Sin.
, vol.30
, Issue.4
, pp. 379-387
-
-
Dong, X.-X.1
Wang, Y.2
Z-H, Q.3
-
15
-
-
19944375450
-
Tau pathology in Alzheimer disease and other tauopathies
-
[15] Iqbal, K., Alonso, A.C., Chen, S., et al. Tau pathology in Alzheimer disease and other tauopathies. BBA-Mol. Basis Dis. 1739:2 (2005), 198–210.
-
(2005)
BBA-Mol. Basis Dis.
, vol.1739
, Issue.2
, pp. 198-210
-
-
Iqbal, K.1
Alonso, A.C.2
Chen, S.3
-
16
-
-
84867608068
-
Tau protein kinases: involvement in Alzheimer's disease
-
[16] Martin, L., Latypova, X., Wilson, C.M., et al. Tau protein kinases: involvement in Alzheimer's disease. Ageing Res. Rev. 12:1 (2013), 289–309.
-
(2013)
Ageing Res. Rev.
, vol.12
, Issue.1
, pp. 289-309
-
-
Martin, L.1
Latypova, X.2
Wilson, C.M.3
-
17
-
-
84903304968
-
The Alzheimer's disease mitochondrial cascade hypothesis: progress and perspectives
-
[17] Swerdlow, R.H., Burns, J.M., Khan, S.M., The Alzheimer's disease mitochondrial cascade hypothesis: progress and perspectives. Biochim. Biophys. Acta Mol. basis Dis. 1842:8 (2014), 1219–1231.
-
(2014)
Biochim. Biophys. Acta Mol. basis Dis.
, vol.1842
, Issue.8
, pp. 1219-1231
-
-
Swerdlow, R.H.1
Burns, J.M.2
Khan, S.M.3
-
18
-
-
84866031913
-
Targeting drugs to mitochondria
-
[18] Heller, A., Brockhoff, G., Goepferich, A., Targeting drugs to mitochondria. Eur. J. Pharm. Biopharm. 82:1 (2012), 1–18.
-
(2012)
Eur. J. Pharm. Biopharm.
, vol.82
, Issue.1
, pp. 1-18
-
-
Heller, A.1
Brockhoff, G.2
Goepferich, A.3
-
19
-
-
84918504163
-
Central nervous system stimulants and drugs that suppress appetite
-
D.R. Sidhartha Elsevier
-
[19] Aagaard, L., Central nervous system stimulants and drugs that suppress appetite. Sidhartha, D.R., (eds.) Side Effects of Drugs Annual, 2014, Elsevier, 1–9.
-
(2014)
Side Effects of Drugs Annual
, pp. 1-9
-
-
Aagaard, L.1
-
20
-
-
56949084877
-
Albumin as a drug carrier: design of prodrugs, drug conjugates and nanoparticles
-
[20] Kratz, F., Albumin as a drug carrier: design of prodrugs, drug conjugates and nanoparticles. J. Control. Release 132:3 (2008), 171–183.
-
(2008)
J. Control. Release
, vol.132
, Issue.3
, pp. 171-183
-
-
Kratz, F.1
-
21
-
-
84961216466
-
Pharmacological, toxicological and neuronal localization assessment of galantamine/chitosan complex nanoparticles in rats: future potential contribution in Alzheimer's disease management
-
[21] Hanafy, A.S., Farid, R.M., Helmy, M.W., et al. Pharmacological, toxicological and neuronal localization assessment of galantamine/chitosan complex nanoparticles in rats: future potential contribution in Alzheimer's disease management. Drug Deliv., 1–12, 2016.
-
(2016)
Drug Deliv.
, vol.1-12
-
-
Hanafy, A.S.1
Farid, R.M.2
Helmy, M.W.3
-
22
-
-
84961618744
-
The “fate” of polymeric and lipid nanoparticles for brain delivery and targeting: strategies and mechanism of blood–brain barrier crossing and trafficking into the central nervous system
-
[22] Tosi, G., Musumeci, T., Ruozi, B., et al. The “fate” of polymeric and lipid nanoparticles for brain delivery and targeting: strategies and mechanism of blood–brain barrier crossing and trafficking into the central nervous system. J. Drug Delivery Sci. Technol. 32 (2016), 66–76.
-
(2016)
J. Drug Delivery Sci. Technol.
, vol.32
, pp. 66-76
-
-
Tosi, G.1
Musumeci, T.2
Ruozi, B.3
-
23
-
-
84927686841
-
Nanoparticles for diagnosis and/or treatment of Alzheimer's disease
-
[23] Antimisiaris, S., Mourtas, S., Markoutsa, E., et al. Nanoparticles for diagnosis and/or treatment of Alzheimer's disease. Adv. Healthc. Mater., 87–179, 2014.
-
(2014)
Adv. Healthc. Mater.
, vol.87-179
-
-
Antimisiaris, S.1
Mourtas, S.2
Markoutsa, E.3
-
24
-
-
84859958800
-
Nanotechnological advances for the delivery of CNS therapeutics
-
[24] Wong, H.L., Wu, X.Y., Bendayan, R., Nanotechnological advances for the delivery of CNS therapeutics. Adv. Drug Deliv. Rev. 64:7 (2012), 686–700.
-
(2012)
Adv. Drug Deliv. Rev.
, vol.64
, Issue.7
, pp. 686-700
-
-
Wong, H.L.1
Wu, X.Y.2
Bendayan, R.3
-
25
-
-
84890941075
-
Current progresses on nanodelivery systems for the treatment of neuropsychiatric diseases: Alzheimer's and Schizophrenia
-
[25] Silva, A., González-Mira, E., Lobo, J.S., et al. Current progresses on nanodelivery systems for the treatment of neuropsychiatric diseases: Alzheimer's and Schizophrenia. Curr. Pharm. Des. 19:41 (2013), 7185–7195.
-
(2013)
Curr. Pharm. Des.
, vol.19
, Issue.41
, pp. 7185-7195
-
-
Silva, A.1
González-Mira, E.2
Lobo, J.S.3
-
26
-
-
84873046533
-
Biocompatibility of engineered nanoparticles for drug delivery
-
[26] Naahidi, S., Jafari, M., Edalat, F., et al. Biocompatibility of engineered nanoparticles for drug delivery. J. Control. Release 166:2 (2013), 182–194.
-
(2013)
J. Control. Release
, vol.166
, Issue.2
, pp. 182-194
-
-
Naahidi, S.1
Jafari, M.2
Edalat, F.3
-
27
-
-
84890924596
-
Advances in nanoparticulate carriers for oral delivery of peptides and proteins: polymeric vs. lipid nanoparticles
-
American Scientific Publishers
-
[27] Silva, A., Santos, D., Ferreira, D., et al. Advances in nanoparticulate carriers for oral delivery of peptides and proteins: polymeric vs. lipid nanoparticles. Encyclopedia of Nanoscience and Nanotechnology, 2011, American Scientific Publishers, 133–146.
-
(2011)
Encyclopedia of Nanoscience and Nanotechnology
, pp. 133-146
-
-
Silva, A.1
Santos, D.2
Ferreira, D.3
-
28
-
-
84960201366
-
PEGylation as a strategy for improving nanoparticle-based drug and gene delivery
-
[28] Suk, J.S., Xu, Q., Kim, N., et al. PEGylation as a strategy for improving nanoparticle-based drug and gene delivery. Adv. Drug Deliv. Rev. 99 (2016), 28–51.
-
(2016)
Adv. Drug Deliv. Rev.
, vol.99
, pp. 28-51
-
-
Suk, J.S.1
Xu, Q.2
Kim, N.3
-
29
-
-
43249095490
-
A nanoparticulate drug-delivery system for rivastigmine: physico-chemical and in vitro biological characterization
-
[29] Craparo, E.F., Pitarresi, G., Bondì, M.L., et al. A nanoparticulate drug-delivery system for rivastigmine: physico-chemical and in vitro biological characterization. Macromol. Biosci. 8:3 (2008), 247–259.
-
(2008)
Macromol. Biosci.
, vol.8
, Issue.3
, pp. 247-259
-
-
Craparo, E.F.1
Pitarresi, G.2
Bondì, M.L.3
-
30
-
-
84936972869
-
Galantamine-loaded PLGA nanoparticles, from nano-emulsion templating, as novel advanced drug delivery systems to treat neurodegenerative diseases
-
[30] Fornaguera, C., Feiner-Gracia, N., Calderó, G., et al. Galantamine-loaded PLGA nanoparticles, from nano-emulsion templating, as novel advanced drug delivery systems to treat neurodegenerative diseases. Nanoscale 7:28 (2015), 12076–12084.
-
(2015)
Nanoscale
, vol.7
, Issue.28
, pp. 12076-12084
-
-
Fornaguera, C.1
Feiner-Gracia, N.2
Calderó, G.3
-
31
-
-
78149410923
-
Formation of polymeric nano-emulsions by a low-energy method and their use for nanoparticle preparation
-
[31] Calderó, G., García-Celma, M.J., Solans, C., Formation of polymeric nano-emulsions by a low-energy method and their use for nanoparticle preparation. J. Colloid Interface Sci. 353:2 (2011), 406–411.
-
(2011)
J. Colloid Interface Sci.
, vol.353
, Issue.2
, pp. 406-411
-
-
Calderó, G.1
García-Celma, M.J.2
Solans, C.3
-
32
-
-
84898997453
-
Donepezil nanosuspension intended for nose to brain targeting: in vitro and in vivo safety evaluation
-
[32] Md, S., Ali, M., Ali, R., et al. Donepezil nanosuspension intended for nose to brain targeting: in vitro and in vivo safety evaluation. Int. J. Biol. Macromol. 67 (2014), 418–425.
-
(2014)
Int. J. Biol. Macromol.
, vol.67
, pp. 418-425
-
-
Md, S.1
Ali, M.2
Ali, R.3
-
33
-
-
84893271973
-
Preparation, characterization, in vivo biodistribution and pharmacokinetic studies of donepezil-loaded PLGA nanoparticles for brain targeting
-
[33] Bhavna, Md, S., Ali, M., et al. Preparation, characterization, in vivo biodistribution and pharmacokinetic studies of donepezil-loaded PLGA nanoparticles for brain targeting. Drug Dev. Ind. Pharm. 40:2 (2014), 278–287.
-
(2014)
Drug Dev. Ind. Pharm.
, vol.40
, Issue.2
, pp. 278-287
-
-
Bhavna1
Md, S.2
Ali, M.3
-
34
-
-
85010071837
-
Donepezil loaded PLGA-b-PEG nanoparticles: their ability to induce destabilization of amyloid fibrils and to cross blood brain barrier in vitro
-
(Vienna, Austria: 1996)
-
[34] Baysal, I., Ucar, G., Gultekinoglu, M., et al. Donepezil loaded PLGA-b-PEG nanoparticles: their ability to induce destabilization of amyloid fibrils and to cross blood brain barrier in vitro. J. Neural Transm., 2016 (Vienna, Austria: 1996).
-
(2016)
J. Neural Transm.
-
-
Baysal, I.1
Ucar, G.2
Gultekinoglu, M.3
-
35
-
-
84949579969
-
Complexation as an approach to entrap cationic drugs into cationic nanoparticles administered intranasally for Alzheimer's disease management: preparation and detection in rat brain
-
[35] Hanafy, A.S., Farid, R.M., ElGamal, S.S., Complexation as an approach to entrap cationic drugs into cationic nanoparticles administered intranasally for Alzheimer's disease management: preparation and detection in rat brain. Drug Dev. Ind. Pharm. 41:12 (2015), 2055–2068.
-
(2015)
Drug Dev. Ind. Pharm.
, vol.41
, Issue.12
, pp. 2055-2068
-
-
Hanafy, A.S.1
Farid, R.M.2
ElGamal, S.S.3
-
36
-
-
84861115952
-
Development and evaluation of rivastigmine loaded chitosan nanoparticles for brain targeting
-
[36] Fazil, M., Md, S., Haque, S., et al. Development and evaluation of rivastigmine loaded chitosan nanoparticles for brain targeting. Eur. J. Pharm. Sci. 47:1 (2012), 6–15.
-
(2012)
Eur. J. Pharm. Sci.
, vol.47
, Issue.1
, pp. 6-15
-
-
Fazil, M.1
Md, S.2
Haque, S.3
-
37
-
-
77957260011
-
Rivastigmine-loaded PLGA and PBCA nanoparticles: preparation, optimization, characterization, in vitro and pharmacodynamic studies
-
[37] Joshi, S.A., Chavhan, S.S., Sawant, K.K., Rivastigmine-loaded PLGA and PBCA nanoparticles: preparation, optimization, characterization, in vitro and pharmacodynamic studies. Eur. J. Pharm. Biopharm. 76:2 (2010), 189–199.
-
(2010)
Eur. J. Pharm. Biopharm.
, vol.76
, Issue.2
, pp. 189-199
-
-
Joshi, S.A.1
Chavhan, S.S.2
Sawant, K.K.3
-
38
-
-
84998654804
-
New-fangled approach in the management of Alzheimer by formulation of polysorbate 80 coated chitosan nanoparticles of rivastigmine for brain delivery and their in vivo evaluation
-
[38] Khemariya, R.P., Khemariya, P.S., New-fangled approach in the management of Alzheimer by formulation of polysorbate 80 coated chitosan nanoparticles of rivastigmine for brain delivery and their in vivo evaluation. International Journal of Current Research in Medical Sciences 2:2 (2016), 18–29.
-
(2016)
International Journal of Current Research in Medical Sciences
, vol.2
, Issue.2
, pp. 18-29
-
-
Khemariya, R.P.1
Khemariya, P.S.2
-
39
-
-
84975206140
-
Galantamine-loaded solid-lipid nanoparticles for enhanced brain delivery: preparation, characterization, in vitro and in vivo evaluations
-
[39] Misra, S., Chopra, K., Sinha, V., et al. Galantamine-loaded solid-lipid nanoparticles for enhanced brain delivery: preparation, characterization, in vitro and in vivo evaluations. Drug Deliv., 1–10, 2015.
-
(2015)
Drug Deliv.
, vol.1-10
-
-
Misra, S.1
Chopra, K.2
Sinha, V.3
-
40
-
-
84924939569
-
Solid lipid nanoparticles loaded with lipoyl–memantine codrug: preparation and characterization
-
[40] Laserra, S., Basit, A., Sozio, P., et al. Solid lipid nanoparticles loaded with lipoyl–memantine codrug: preparation and characterization. Int. J. Pharm. 485:1 (2015), 183–191.
-
(2015)
Int. J. Pharm.
, vol.485
, Issue.1
, pp. 183-191
-
-
Laserra, S.1
Basit, A.2
Sozio, P.3
-
41
-
-
84936995824
-
Application of quality by design approach for intranasal delivery of rivastigmine loaded solid lipid nanoparticles: effect on formulation and characterization parameters
-
[41] Shah, B., Khunt, D., Bhatt, H., et al. Application of quality by design approach for intranasal delivery of rivastigmine loaded solid lipid nanoparticles: effect on formulation and characterization parameters. Eur. J. Pharm. Sci. 78 (2015), 54–66.
-
(2015)
Eur. J. Pharm. Sci.
, vol.78
, pp. 54-66
-
-
Shah, B.1
Khunt, D.2
Bhatt, H.3
-
42
-
-
84873053242
-
Potential therapeutic effect of nanobased formulation of rivastigmine on rat model of Alzheimer's disease
-
[42] Ismail, M.F., ElMeshad, A.N., Salem, N.A.-H., Potential therapeutic effect of nanobased formulation of rivastigmine on rat model of Alzheimer's disease. Int. J. Nanomedicine, 8, 2013, 393.
-
(2013)
Int. J. Nanomedicine
, vol.8
, pp. 393
-
-
Ismail, M.F.1
ElMeshad, A.N.2
Salem, N.A.-H.3
-
43
-
-
84955139262
-
Preparation, characterization, and in vivo evaluation of intranasally administered liposomal formulation of donepezil
-
[43] Al Asmari, A.K., Ullah, Z., Tariq, M., et al. Preparation, characterization, and in vivo evaluation of intranasally administered liposomal formulation of donepezil. Drug Des. Devel. Ther, 10, 2016, 205.
-
(2016)
Drug Des. Devel. Ther
, vol.10
, pp. 205
-
-
Al Asmari, A.K.1
Ullah, Z.2
Tariq, M.3
-
44
-
-
84884206111
-
Enhanced brain distribution and pharmacodynamics of rivastigmine by liposomes following intranasal administration
-
[44] Yang, Z.-Z., Zhang, Y.-Q., Wang, Z.-Z., et al. Enhanced brain distribution and pharmacodynamics of rivastigmine by liposomes following intranasal administration. Int. J. Pharm. 452:1 (2013), 344–354.
-
(2013)
Int. J. Pharm.
, vol.452
, Issue.1
, pp. 344-354
-
-
Yang, Z.-Z.1
Zhang, Y.-Q.2
Wang, Z.-Z.3
-
45
-
-
84861158528
-
Pharmacokinetic behavior and efficiency of acetylcholinesterase inhibition in rat brain after intranasal administration of galanthamine hydrobromide loaded flexible liposomes
-
[45] Li, W., Zhou, Y., Zhao, N., et al. Pharmacokinetic behavior and efficiency of acetylcholinesterase inhibition in rat brain after intranasal administration of galanthamine hydrobromide loaded flexible liposomes. Environ. Toxicol. Pharmacol. 34:2 (2012), 272–279.
-
(2012)
Environ. Toxicol. Pharmacol.
, vol.34
, Issue.2
, pp. 272-279
-
-
Li, W.1
Zhou, Y.2
Zhao, N.3
-
46
-
-
84888341127
-
Amyloid-binding aptamer conjugated curcumin–PLGA nanoparticle for potential use in Alzheimer's disease
-
[46] Mathew, A., Aravind, A., Brahatheeswaran, D., et al. Amyloid-binding aptamer conjugated curcumin–PLGA nanoparticle for potential use in Alzheimer's disease. BioNanoScience 2:2 (2012), 83–93.
-
(2012)
BioNanoScience
, vol.2
, Issue.2
, pp. 83-93
-
-
Mathew, A.1
Aravind, A.2
Brahatheeswaran, D.3
-
47
-
-
82755175075
-
Lipid nanoparticles in biomedicine
-
American Scientific Publishers
-
[47] Estella-Hermoso de Mendoza, A., Lasa-Saracibar, B., Campanero, M., et al. Lipid nanoparticles in biomedicine. Encyclopedia of Nanoscience and Nanotechnology, 2011, American Scientific Publishers, 455–478.
-
(2011)
Encyclopedia of Nanoscience and Nanotechnology
, pp. 455-478
-
-
Estella-Hermoso de Mendoza, A.1
Lasa-Saracibar, B.2
Campanero, M.3
-
48
-
-
84899689651
-
Drug targeting using solid lipid nanoparticles
-
[48] Rostami, E., Kashanian, S., Azandaryani, A.H., et al. Drug targeting using solid lipid nanoparticles. Chem. Phys. Lipids 181 (2014), 56–61.
-
(2014)
Chem. Phys. Lipids
, vol.181
, pp. 56-61
-
-
Rostami, E.1
Kashanian, S.2
Azandaryani, A.H.3
-
49
-
-
84949556196
-
Effect of sterilization on the physical stability of brimonidine-loaded solid lipid nanoparticles and nanostructured lipid carriers
-
[49] El-Salamouni, N.S., Farid, R.M., El-Kamel, A.H., et al. Effect of sterilization on the physical stability of brimonidine-loaded solid lipid nanoparticles and nanostructured lipid carriers. Int. J. Pharm. 496:2 (2015), 976–983.
-
(2015)
Int. J. Pharm.
, vol.496
, Issue.2
, pp. 976-983
-
-
El-Salamouni, N.S.1
Farid, R.M.2
El-Kamel, A.H.3
-
50
-
-
65949093025
-
Ferulic acid-loaded lipid nanostructures as drug delivery systems for Alzheimer's disease: preparation, characterization and cytotoxicity studies
-
[50] Bondi, M., Montana, G., Craparo, E., et al. Ferulic acid-loaded lipid nanostructures as drug delivery systems for Alzheimer's disease: preparation, characterization and cytotoxicity studies. Curr. Nanosci. 5:1 (2009), 26–32.
-
(2009)
Curr. Nanosci.
, vol.5
, Issue.1
, pp. 26-32
-
-
Bondi, M.1
Montana, G.2
Craparo, E.3
-
52
-
-
84957552037
-
Antitumoral-lipid-based nanoparticles: a platform for future application in osteosarcoma therapy
-
[52] Gonzalez-Fernandez, Y., Imbuluzqueta, E., Patino-Garcia, A., et al. Antitumoral-lipid-based nanoparticles: a platform for future application in osteosarcoma therapy. Curr. Pharm. Des. 21:42 (2015), 6104–6124.
-
(2015)
Curr. Pharm. Des.
, vol.21
, Issue.42
, pp. 6104-6124
-
-
Gonzalez-Fernandez, Y.1
Imbuluzqueta, E.2
Patino-Garcia, A.3
-
53
-
-
37849010813
-
Lipid nanoparticles for alkyl lysophospholipid edelfosine encapsulation: development and in vitro characterization
-
Feb
-
[53] Estella-Hermoso de Mendoza, A., Rayo, M., Mollinedo, F., et al. Lipid nanoparticles for alkyl lysophospholipid edelfosine encapsulation: development and in vitro characterization. Eur. J. Pharm. Biopharm. 68:2 (Feb 2008), 207–213.
-
(2008)
Eur. J. Pharm. Biopharm.
, vol.68
, Issue.2
, pp. 207-213
-
-
Estella-Hermoso de Mendoza, A.1
Rayo, M.2
Mollinedo, F.3
-
54
-
-
84896837155
-
Lecithin-based nanostructured gels for skin delivery: an update on state of art and recent applications
-
[54] Elnaggar, Y.S., El-Refaie, W.M., El-Massik, M.A., et al. Lecithin-based nanostructured gels for skin delivery: an update on state of art and recent applications. J. Control. Release 180 (2014), 10–24.
-
(2014)
J. Control. Release
, vol.180
, pp. 10-24
-
-
Elnaggar, Y.S.1
El-Refaie, W.M.2
El-Massik, M.A.3
-
55
-
-
84938741225
-
Novel self-assembled, gel-core hyaluosomes for non-invasive management of osteoarthritis: in vitro optimization, ex vivo and in vivo permeation
-
[55] El-Refaie, W.M., Elnaggar, Y.S., El-Massik, M.A., et al. Novel self-assembled, gel-core hyaluosomes for non-invasive management of osteoarthritis: in vitro optimization, ex vivo and in vivo permeation. Pharm. Res. 32 (2015), 2901–2911.
-
(2015)
Pharm. Res.
, vol.32
, pp. 2901-2911
-
-
El-Refaie, W.M.1
Elnaggar, Y.S.2
El-Massik, M.A.3
-
56
-
-
34447285025
-
Cationic transfersomes based topical genetic vaccine against hepatitis B
-
[56] Mahor, S., Rawat, A., Dubey, P.K., et al. Cationic transfersomes based topical genetic vaccine against hepatitis B. Int. J. Pharm. 340:1 (2007), 13–19.
-
(2007)
Int. J. Pharm.
, vol.340
, Issue.1
, pp. 13-19
-
-
Mahor, S.1
Rawat, A.2
Dubey, P.K.3
-
57
-
-
84879977264
-
Lyophilized phytosomal nanocarriers as platforms for enhanced diosmin delivery: optimization and ex vivo permeation
-
[57] Freag, M.S., Elnaggar, Y.S., Abdallah, O.Y., Lyophilized phytosomal nanocarriers as platforms for enhanced diosmin delivery: optimization and ex vivo permeation. Int. J. Nanomedicine 8 (2013), 2385–2397.
-
(2013)
Int. J. Nanomedicine
, vol.8
, pp. 2385-2397
-
-
Freag, M.S.1
Elnaggar, Y.S.2
Abdallah, O.Y.3
-
58
-
-
84866737577
-
Improvement of drug safety by the use of lipid-based nanocarriers
-
[58] Lim, S.B., Banerjee, A., Önyüksel, H., Improvement of drug safety by the use of lipid-based nanocarriers. J. Control. Release 163:1 (2012), 34–45.
-
(2012)
J. Control. Release
, vol.163
, Issue.1
, pp. 34-45
-
-
Lim, S.B.1
Banerjee, A.2
Önyüksel, H.3
-
59
-
-
14144250911
-
Recent advances with liposomes as pharmaceutical carriers
-
[59] Torchilin, V.P., Recent advances with liposomes as pharmaceutical carriers. Nat. Rev. Drug Discov. 4:2 (2005), 145–160.
-
(2005)
Nat. Rev. Drug Discov.
, vol.4
, Issue.2
, pp. 145-160
-
-
Torchilin, V.P.1
-
60
-
-
84861051659
-
Current trends in liposome research
-
Pharmaceutical Nanocarriers: Humana Press
-
[60] ElBayoumi, T.A., Torchilin, V.P., Current trends in liposome research. Liposomes: Methods and Protocols, vol. 1, 2010, Pharmaceutical Nanocarriers: Humana Press, 1–27.
-
(2010)
Liposomes: Methods and Protocols
, vol.1
, pp. 1-27
-
-
ElBayoumi, T.A.1
Torchilin, V.P.2
-
61
-
-
63149175757
-
Delivery of peptide and protein drugs over the blood–brain barrier
-
[61] Brasnjevic, I., Steinbusch, H.W., Schmitz, C., et al. Delivery of peptide and protein drugs over the blood–brain barrier. Prog. Neurobiol. 87:4 (2009), 212–251.
-
(2009)
Prog. Neurobiol.
, vol.87
, Issue.4
, pp. 212-251
-
-
Brasnjevic, I.1
Steinbusch, H.W.2
Schmitz, C.3
-
62
-
-
39049171058
-
Liposomal nanomedicines
-
[62] Fenske, D.B., Cullis, P.R., Liposomal nanomedicines. Expert Opin. Drug Deliv. 5:1 (2008), 25–44.
-
(2008)
Expert Opin. Drug Deliv.
, vol.5
, Issue.1
, pp. 25-44
-
-
Fenske, D.B.1
Cullis, P.R.2
-
63
-
-
84861311174
-
Liposomes for targeted delivery of active agents against neurodegenerative diseases (Alzheimer's disease and Parkinson's disease)
-
[63] Spuch, C., Navarro, C., Liposomes for targeted delivery of active agents against neurodegenerative diseases (Alzheimer's disease and Parkinson's disease). Journal of Drug Delivery, 2011, 2011.
-
(2011)
Journal of Drug Delivery
, vol.2011
-
-
Spuch, C.1
Navarro, C.2
-
64
-
-
31044441421
-
Longitudinal PET evaluation of cerebral glucose metabolism in rivastigmine treated patients with mild Alzheimer's disease
-
[64] Stefanova, E., Wall, A., Almkvist, O., et al. Longitudinal PET evaluation of cerebral glucose metabolism in rivastigmine treated patients with mild Alzheimer's disease. J. Neural Transm. 113:2 (2006), 205–218.
-
(2006)
J. Neural Transm.
, vol.113
, Issue.2
, pp. 205-218
-
-
Stefanova, E.1
Wall, A.2
Almkvist, O.3
-
65
-
-
84887922844
-
Targeted drug delivery across the blood brain barrier in Alzheimer's disease
-
[65] Rocha, S., Targeted drug delivery across the blood brain barrier in Alzheimer's disease. Curr. Pharm. Des. 19:37 (2013), 6635–6646.
-
(2013)
Curr. Pharm. Des.
, vol.19
, Issue.37
, pp. 6635-6646
-
-
Rocha, S.1
-
66
-
-
84857543329
-
Nanotechnologies: a strategy to overcome blood–brain barrier
-
[66] De Rosa, G., Salzano, G., Caraglia, M., et al. Nanotechnologies: a strategy to overcome blood–brain barrier. Curr. Drug Metab. 13:1 (2012), 61–69.
-
(2012)
Curr. Drug Metab.
, vol.13
, Issue.1
, pp. 61-69
-
-
De Rosa, G.1
Salzano, G.2
Caraglia, M.3
-
67
-
-
84928128382
-
Parameters and characteristics governing cellular internalization and trans-barrier trafficking of nanostructures
-
[67] Murugan, K., Choonara, Y.E., Kumar, P., et al. Parameters and characteristics governing cellular internalization and trans-barrier trafficking of nanostructures. Int. J. Nanomedicine, 10, 2015, 2191.
-
(2015)
Int. J. Nanomedicine
, vol.10
, pp. 2191
-
-
Murugan, K.1
Choonara, Y.E.2
Kumar, P.3
-
68
-
-
84907508928
-
Designing the future of nanomedicine: current barriers to targeted brain therapeutics
-
[68] Herda, L.M., Polo, E., Kelly, P.M., et al. Designing the future of nanomedicine: current barriers to targeted brain therapeutics. Eur. J. Nanomed. 6:3 (2014), 127–139.
-
(2014)
Eur. J. Nanomed.
, vol.6
, Issue.3
, pp. 127-139
-
-
Herda, L.M.1
Polo, E.2
Kelly, P.M.3
-
69
-
-
82755182780
-
In vitro and in vivo efficacy of edelfosine-loaded lipid nanoparticles against glioma
-
[69] Estella-Hermoso de Mendoza, A., Preat, V., Mollinedo, F., et al. In vitro and in vivo efficacy of edelfosine-loaded lipid nanoparticles against glioma. J. Control. Release 156:3 (2011), 421–426.
-
(2011)
J. Control. Release
, vol.156
, Issue.3
, pp. 421-426
-
-
Estella-Hermoso de Mendoza, A.1
Preat, V.2
Mollinedo, F.3
-
71
-
-
84899518848
-
Multifunctional nanoliposomes with curcumin–lipid derivative and brain targeting functionality with potential applications for Alzheimer disease
-
[71] Mourtas, S., Lazar, A.N., Markoutsa, E., et al. Multifunctional nanoliposomes with curcumin–lipid derivative and brain targeting functionality with potential applications for Alzheimer disease. Eur. J. Med. Chem. 80 (2014), 175–183.
-
(2014)
Eur. J. Med. Chem.
, vol.80
, pp. 175-183
-
-
Mourtas, S.1
Lazar, A.N.2
Markoutsa, E.3
-
72
-
-
84878024482
-
Functionalization with TAT-peptide enhances blood–brain barrier crossing in vitro of nanoliposomes carrying a curcumin-derivative to bind amyloid-Î peptide
-
[72] Sancini, G., Gregori, M., Salvati, E., et al. Functionalization with TAT-peptide enhances blood–brain barrier crossing in vitro of nanoliposomes carrying a curcumin-derivative to bind amyloid-Î peptide. J. Nanomed. Nanotechnol., 2013, 2013.
-
(2013)
J. Nanomed. Nanotechnol.
, vol.2013
-
-
Sancini, G.1
Gregori, M.2
Salvati, E.3
-
73
-
-
84899523576
-
Mono and dually decorated nanoliposomes for brain targeting, in vitro and in vivo studies
-
[73] Markoutsa, E., Papadia, K., Giannou, A., et al. Mono and dually decorated nanoliposomes for brain targeting, in vitro and in vivo studies. Pharm. Res. 31:5 (2014), 1275–1289.
-
(2014)
Pharm. Res.
, vol.31
, Issue.5
, pp. 1275-1289
-
-
Markoutsa, E.1
Papadia, K.2
Giannou, A.3
-
74
-
-
84957078663
-
The hunt for brain Aβ oligomers by peripherally circulating multi-functional nanoparticles: potential therapeutic approach for Alzheimer disease
-
[74] Mancini, S., Minniti, S., Gregori, M., et al. The hunt for brain Aβ oligomers by peripherally circulating multi-functional nanoparticles: potential therapeutic approach for Alzheimer disease. Nanomedicine: Nanotechnology, Biology and Medicine 12:1 (2016), 43–52.
-
(2016)
Nanomedicine: Nanotechnology, Biology and Medicine
, vol.12
, Issue.1
, pp. 43-52
-
-
Mancini, S.1
Minniti, S.2
Gregori, M.3
-
75
-
-
41849118077
-
The properties of liposomes produced from milk fat globule membrane material using different techniques
-
[75] Thompson, A.K., Mozafari, M.R., Singh, H., The properties of liposomes produced from milk fat globule membrane material using different techniques. Lait 87:4–5 (2007), 349–360.
-
(2007)
Lait
, vol.87
, Issue.4-5
, pp. 349-360
-
-
Thompson, A.K.1
Mozafari, M.R.2
Singh, H.3
-
76
-
-
79953685905
-
Nanonization strategies for poorly water-soluble drugs
-
[76] Chen, H., Khemtong, C., Yang, X., et al. Nanonization strategies for poorly water-soluble drugs. Drug Discov. Today 16:7 (2011), 354–360.
-
(2011)
Drug Discov. Today
, vol.16
, Issue.7
, pp. 354-360
-
-
Chen, H.1
Khemtong, C.2
Yang, X.3
-
77
-
-
85028127551
-
Polymeric micelles and alternative nanonized delivery vehicles for poorly soluble drugs
-
[77] Lu, Y., Park, K., Polymeric micelles and alternative nanonized delivery vehicles for poorly soluble drugs. Int. J. Pharm. 453:1 (2013), 198–214.
-
(2013)
Int. J. Pharm.
, vol.453
, Issue.1
, pp. 198-214
-
-
Lu, Y.1
Park, K.2
-
78
-
-
84865758788
-
Lipid-based nanocarriers as an alternative for oral delivery of poorly water-soluble drugs: peroral and mucosal routes
-
[78] Silva, A.C., Santos, D., Ferreira, D., et al. Lipid-based nanocarriers as an alternative for oral delivery of poorly water-soluble drugs: peroral and mucosal routes. Curr. Med. Chem. 19:26 (2012), 4495–4510.
-
(2012)
Curr. Med. Chem.
, vol.19
, Issue.26
, pp. 4495-4510
-
-
Silva, A.C.1
Santos, D.2
Ferreira, D.3
-
79
-
-
84885227307
-
Optimization of curcumin nanoemulsion for intranasal delivery using design of experiment and its toxicity assessment
-
[79] Sood, S., Jain, K., Gowthamarajan, K., Optimization of curcumin nanoemulsion for intranasal delivery using design of experiment and its toxicity assessment. Colloids Surf. B: Biointerfaces 113 (2014), 330–337.
-
(2014)
Colloids Surf. B: Biointerfaces
, vol.113
, pp. 330-337
-
-
Sood, S.1
Jain, K.2
Gowthamarajan, K.3
-
80
-
-
85015635203
-
Development of an optimized hyaluronic acid-based lipidic nanoemulsion co-encapsulating two polyphenols for nose to brain delivery
-
[80] Nasr, M., Development of an optimized hyaluronic acid-based lipidic nanoemulsion co-encapsulating two polyphenols for nose to brain delivery. Drug Deliv., 1–9, 2015.
-
(2015)
Drug Deliv.
, vol.1-9
-
-
Nasr, M.1
-
81
-
-
84957899809
-
Nanoemulsions loaded Carbopol® 934 based gel for intranasal delivery of neuroprotective Centella asiatica extract: in-vitro and ex-vivo permeation study
-
[81] Jaiswal, M., Kumar, A., Sharma, S., Nanoemulsions loaded Carbopol® 934 based gel for intranasal delivery of neuroprotective Centella asiatica extract: in-vitro and ex-vivo permeation study. J. Pharm. Investig. 46:1 (2016), 79–89.
-
(2016)
J. Pharm. Investig.
, vol.46
, Issue.1
, pp. 79-89
-
-
Jaiswal, M.1
Kumar, A.2
Sharma, S.3
-
82
-
-
84890345966
-
A critical appraisal of microemulsions for drug delivery: part I
-
[82] Sapra, B., Thatai, P., Bhandari, S., et al. A critical appraisal of microemulsions for drug delivery: part I. Ther. Deliv. 4:12 (2013), 1547–1564.
-
(2013)
Ther. Deliv.
, vol.4
, Issue.12
, pp. 1547-1564
-
-
Sapra, B.1
Thatai, P.2
Bhandari, S.3
-
83
-
-
84870248465
-
Microemulsion-based media as novel drug delivery systems
-
[83] Lawrence, M.J., Rees, G.D., Microemulsion-based media as novel drug delivery systems. Adv. Drug Deliv. Rev. 64 (2012), 175–193.
-
(2012)
Adv. Drug Deliv. Rev.
, vol.64
, pp. 175-193
-
-
Lawrence, M.J.1
Rees, G.D.2
-
84
-
-
84942892337
-
Nose to brain microemulsion-based drug delivery system of rivastigmine: formulation and ex-vivo characterization
-
[84] Shah, B.M., Misra, M., Shishoo, C.J., et al. Nose to brain microemulsion-based drug delivery system of rivastigmine: formulation and ex-vivo characterization. Drug Deliv. 22:7 (2015), 918–930.
-
(2015)
Drug Deliv.
, vol.22
, Issue.7
, pp. 918-930
-
-
Shah, B.M.1
Misra, M.2
Shishoo, C.J.3
-
85
-
-
84860358563
-
Microemulsion-based patch for transdermal delivery of huperzine A and ligustrazine phosphate in treatment of Alzheimer's disease
-
[85] Shi, J., Cong, W., Wang, Y., et al. Microemulsion-based patch for transdermal delivery of huperzine A and ligustrazine phosphate in treatment of Alzheimer's disease. Drug Dev. Ind. Pharm. 38:6 (2012), 752–761.
-
(2012)
Drug Dev. Ind. Pharm.
, vol.38
, Issue.6
, pp. 752-761
-
-
Shi, J.1
Cong, W.2
Wang, Y.3
-
86
-
-
0033119135
-
Dendrimers: from design to application—a progress report
-
[86] Fischer, M., Vögtle, F., Dendrimers: from design to application—a progress report. Angew. Chem. Int. Ed. 38:7 (1999), 884–905.
-
(1999)
Angew. Chem. Int. Ed.
, vol.38
, Issue.7
, pp. 884-905
-
-
Fischer, M.1
Vögtle, F.2
-
87
-
-
0003518691
-
Dendritic Molecules: Concepts, Syntheses, Perspectives
-
Wiley VCH
-
[87] Moorefield, C.N., Vögtle, F., Dendritic Molecules: Concepts, Syntheses, Perspectives. 2008, Wiley VCH.
-
(2008)
-
-
Moorefield, C.N.1
Vögtle, F.2
-
88
-
-
0021586266
-
A new class of polymers: starburst-dendritic
-
[88] Tomalia, D., Baker, H., Dewald, J., et al. A new class of polymers: starburst-dendritic. Polym. J. 17:1 (1985), 117–132.
-
(1985)
Polym. J.
, vol.17
, Issue.1
, pp. 117-132
-
-
Tomalia, D.1
Baker, H.2
Dewald, J.3
-
89
-
-
81255152309
-
Dense shell glycodendrimers as potential nontoxic anti-amyloidogenic agents in Alzheimer's disease. Amyloid–dendrimer aggregates morphology and cell toxicity
-
[89] Klementieva, O., Benseny-Cases, N., Gella, A., et al. Dense shell glycodendrimers as potential nontoxic anti-amyloidogenic agents in Alzheimer's disease. Amyloid–dendrimer aggregates morphology and cell toxicity. Biomacromolecules 12:11 (2011), 3903–3909.
-
(2011)
Biomacromolecules
, vol.12
, Issue.11
, pp. 3903-3909
-
-
Klementieva, O.1
Benseny-Cases, N.2
Gella, A.3
-
91
-
-
84903185308
-
Research and development of anti-Alzheimer's drugs: an analysis based on technology flows measured by patent citations
-
[91] Xu, J., Kong, X., Qiu, L., et al. Research and development of anti-Alzheimer's drugs: an analysis based on technology flows measured by patent citations. Expert Opin. Ther. Pat. 24:7 (2014), 791–800.
-
(2014)
Expert Opin. Ther. Pat.
, vol.24
, Issue.7
, pp. 791-800
-
-
Xu, J.1
Kong, X.2
Qiu, L.3
-
92
-
-
84998817874
-
Dose-finding Study to Evaluate Safety, Tolerability, and Efficacy of E2609 in Subjects With Mild Cognitive Impairment Due to Alzheimer's Disease (Prodromal Alzheimer's Disease) and Mild to Moderate Dementia Due to Alzheimer's Disease
-
[March 3, 2016]; Available from:
-
[92] NCT02322021, Dose-finding Study to Evaluate Safety, Tolerability, and Efficacy of E2609 in Subjects With Mild Cognitive Impairment Due to Alzheimer's Disease (Prodromal Alzheimer's Disease) and Mild to Moderate Dementia Due to Alzheimer's Disease. [March 3, 2016]; Available from: https://clinicaltrials.gov/ct2/show/NCT02322021, 2016.
-
(2016)
-
-
NCT023220211
-
93
-
-
84975840790
-
Anti-obesity effect of intranasal administration of galanin-like peptide (GALP) in obese mice
-
[93] Kageyama, H., Shiba, K., Hirako, S., et al. Anti-obesity effect of intranasal administration of galanin-like peptide (GALP) in obese mice. Sci. Rep., 6, 2016.
-
(2016)
Sci. Rep.
, vol.6
-
-
Kageyama, H.1
Shiba, K.2
Hirako, S.3
-
94
-
-
79961088853
-
Evaluation of the rabbit nasal cavity in inhalation studies and a comparison with other common laboratory species and man
-
[94] Pereira, M.E., Macri, N.P., Creasy, D.M., Evaluation of the rabbit nasal cavity in inhalation studies and a comparison with other common laboratory species and man. Toxicol. Pathol. 39:5 (2011), 893–900.
-
(2011)
Toxicol. Pathol.
, vol.39
, Issue.5
, pp. 893-900
-
-
Pereira, M.E.1
Macri, N.P.2
Creasy, D.M.3
-
95
-
-
84998756413
-
Galantamine, Donepezil, Rivastigmine and Memantine
-
[cited 2016 March 1]; Available from:
-
[95] Galantamine, Donepezil, Rivastigmine and Memantine. [cited 2016 March 1]; Available from: https://www.drugs.com/, 2016.
-
(2016)
-
-
-
96
-
-
84927686841
-
Nanoparticles for diagnosis and/or treatment of Alzheimer's disease
-
A. Tiwari John Wiley & Sons, Inc. New Jersy, USA
-
[96] Antimisiaris, S.G., Mourtas, S., Markoutsa, E., et al. Nanoparticles for diagnosis and/or treatment of Alzheimer's disease. Tiwari, A., (eds.) Advanced Healthcare Materials, 2014, John Wiley & Sons, Inc., New Jersy, USA, 87–179.
-
(2014)
Advanced Healthcare Materials
, pp. 87-179
-
-
Antimisiaris, S.G.1
Mourtas, S.2
Markoutsa, E.3
-
97
-
-
84871115007
-
Design and evaluation of chitosan nanoparticles as novel drug carriers for the delivery of donepezil
-
[97] Raja Azalea, D., Mohambed, M., Joji, S., et al. Design and evaluation of chitosan nanoparticles as novel drug carriers for the delivery of donepezil. Iranian Journal of Pharmaceutical Sciences 8:3 (2012), 155–164.
-
(2012)
Iranian Journal of Pharmaceutical Sciences
, vol.8
, Issue.3
, pp. 155-164
-
-
Raja Azalea, D.1
Mohambed, M.2
Joji, S.3
-
98
-
-
84860011902
-
Polymeric nanoparticles for drug delivery to the central nervous system
-
[98] Patel, T., Zhou, J., Piepmeier, J.M., et al. Polymeric nanoparticles for drug delivery to the central nervous system. Adv. Drug Deliv. Rev. 64:7 (2012), 701–705.
-
(2012)
Adv. Drug Deliv. Rev.
, vol.64
, Issue.7
, pp. 701-705
-
-
Patel, T.1
Zhou, J.2
Piepmeier, J.M.3
-
99
-
-
84904251850
-
Solid lipid nanoparticles as vehicles of drugs to the brain: current state of the art
-
[99] Gastaldi, L., Battaglia, L., Peira, E., Chirio, D., Muntoni, E., Solazzi, I., Gallarate, M., Dosio, F., Solid lipid nanoparticles as vehicles of drugs to the brain: current state of the art. European Journal of Pharmaceutics and Biopharmaceutics 87:3 (2014), 433–444.
-
(2014)
European Journal of Pharmaceutics and Biopharmaceutics
, vol.87
, Issue.3
, pp. 433-444
-
-
Gastaldi, L.1
Battaglia, L.2
Peira, E.3
Chirio, D.4
Muntoni, E.5
Solazzi, I.6
Gallarate, M.7
Dosio, F.8
-
100
-
-
84873252557
-
Liposomal drug delivery systems: from concept to clinical applications
-
[100] Allen, T.M., Cullis, P.R., Liposomal drug delivery systems: from concept to clinical applications. Advanced drug delivery reviews 65:1 (2013), 36–48.
-
(2013)
Advanced drug delivery reviews
, vol.65
, Issue.1
, pp. 36-48
-
-
Allen, T.M.1
Cullis, P.R.2
-
101
-
-
24644519939
-
Engineering of nanoemulsions for drug delivery
-
[101] Sarker, D.K., Engineering of nanoemulsions for drug delivery. Current Drug Delivery 2:4 (2005), 297–310.
-
(2005)
Current Drug Delivery
, vol.2
, Issue.4
, pp. 297-310
-
-
Sarker, D.K.1
-
102
-
-
84883856935
-
Nanotechnology-based drug delivery systems for targeting, imaging and diagnosis of neurodegenerative diseases
-
[102] Bozdağ, P.S., Nanotechnology-based drug delivery systems for targeting, imaging and diagnosis of neurodegenerative diseases. Pharm. Res. 30:10 (2013), 2499–2511.
-
(2013)
Pharm. Res.
, vol.30
, Issue.10
, pp. 2499-2511
-
-
Bozdağ, P.S.1
-
103
-
-
84928693876
-
Diagnostic and therapeutic uses of nanomaterials in the brain
-
[103] Garbayo, E., Estella-Hermoso de Mendoza, A., Blanco-Prieto, M.J., Diagnostic and therapeutic uses of nanomaterials in the brain. Curr. Med. Chem. 21:36 (2014), 4100–4131.
-
(2014)
Curr. Med. Chem.
, vol.21
, Issue.36
, pp. 4100-4131
-
-
Garbayo, E.1
Estella-Hermoso de Mendoza, A.2
Blanco-Prieto, M.J.3
-
104
-
-
84944447830
-
Rivastigmine for Alzheimer's disease
-
[104] Birks, J.G.E.J., Iakovidou, V., Tsolaki, M., Holt, F.E., Rivastigmine for Alzheimer's disease. Cochrane Database Syst. Rev., 2, 2015, CD001191.
-
(2015)
Cochrane Database Syst. Rev.
, vol.2
-
-
Birks, J.G.E.J.1
Iakovidou, V.2
Tsolaki, M.3
Holt, F.E.4
-
105
-
-
37649026816
-
Donepezil for dementia due to Alzheimer's disease
-
[105] Birks, J.H.R., Donepezil for dementia due to Alzheimer's disease. Cochrane Database Syst. Rev., 1, 2006, CD001190.
-
(2006)
Cochrane Database Syst. Rev.
, vol.1
-
-
Birks, J.H.R.1
-
106
-
-
33645510613
-
Galantamine for Alzheimer's disease and mild cognitive impairment
-
[106] Loy, C.S.L., Galantamine for Alzheimer's disease and mild cognitive impairment. Cochrane Database Syst. Rev., 1, 2006, CD001747.
-
(2006)
Cochrane Database Syst. Rev.
, vol.1
-
-
Loy, C.S.L.1
-
107
-
-
84998715754
-
Memantine Hydrochloride
-
[cited 2016 March 1]; Available from:
-
[107] European Medicines Agency, Memantine Hydrochloride. [cited 2016 March 1]; Available from: http://www.ema.europa.eu.
-
-
-
European Medicines Agency1
-
108
-
-
33947283745
-
Safety and tolerability of once-daily versus twice-daily memantine: a randomised, double-blind study in moderate to severe Alzheimer's disease
-
[108] Jones, R.W., Bayer, A., Inglis, F., et al. Safety and tolerability of once-daily versus twice-daily memantine: a randomised, double-blind study in moderate to severe Alzheimer's disease. Int. J. Geriatr. Psychiatry 22:3 (2007), 258–262.
-
(2007)
Int. J. Geriatr. Psychiatry
, vol.22
, Issue.3
, pp. 258-262
-
-
Jones, R.W.1
Bayer, A.2
Inglis, F.3
-
109
-
-
84877601800
-
Safety and efficacy of memantine extended-release in the management of Alzheimer's disease
-
[109] Corbett, A., Francis, P., Ballard, C., Safety and efficacy of memantine extended-release in the management of Alzheimer's disease. Clin. Med. Insights Ther. 5 (2013), 95–102.
-
(2013)
Clin. Med. Insights Ther.
, vol.5
, pp. 95-102
-
-
Corbett, A.1
Francis, P.2
Ballard, C.3
-
110
-
-
44949217683
-
Huperzine A for Alzheimer's disease
-
[110] Li, J., Wu, H.M., Zhou, R.L., Liu, G.J., Dong, B.R., Huperzine A for Alzheimer's disease. Cochrane Database Syst. Rev., 2, 2008.
-
(2008)
Cochrane Database Syst. Rev.
, vol.2
-
-
Li, J.1
Wu, H.M.2
Zhou, R.L.3
Liu, G.J.4
Dong, B.R.5
-
111
-
-
84879509747
-
Nanotechnology for CNS delivery of bio-therapeutic agents
-
[111] Amiji, LSSYM, Nanotechnology for CNS delivery of bio-therapeutic agents. Drug Deliv. Transl. Res. 3 (2013), 336–351.
-
(2013)
Drug Deliv. Transl. Res.
, vol.3
, pp. 336-351
-
-
Amiji1
LSSYM2
-
112
-
-
84938367332
-
Challenges and new strategies for therapeutic peptide delivery to the CNS
-
[112] McGowan, J.W., Bidwell, G.L. III, Vig, P.J., Challenges and new strategies for therapeutic peptide delivery to the CNS. Ther. Deliv. 6:7 (2015), 841–853.
-
(2015)
Ther. Deliv.
, vol.6
, Issue.7
, pp. 841-853
-
-
McGowan, J.W.1
Bidwell, G.L.2
Vig, P.J.3
-
113
-
-
69949165507
-
Commentary on “Alzheimer's disease drug development and the problem of the blood–brain barrier”
-
[113] S, J.W., Commentary on “Alzheimer's disease drug development and the problem of the blood–brain barrier”. Alzheimers Dement. 5:5 (2009), 433–434.
-
(2009)
Alzheimers Dement.
, vol.5
, Issue.5
, pp. 433-434
-
-
S, J.W.1
-
114
-
-
84999006812
-
-
Available from:
-
[114] ClinicalTrials.org, Available from: https://clinicaltrials.gov/, 2016.
-
(2016)
-
-
ClinicalTrials.org1
-
115
-
-
42649120973
-
Nanotechnology in vaccine delivery
-
[115] Peek, L.J., Middaugh, C.R., Berkland, C., Nanotechnology in vaccine delivery. Adv. Drug Deliv. Rev. 60:8 (2008), 915–928.
-
(2008)
Adv. Drug Deliv. Rev.
, vol.60
, Issue.8
, pp. 915-928
-
-
Peek, L.J.1
Middaugh, C.R.2
Berkland, C.3
-
116
-
-
84895436939
-
Nanotoxicity overview: nano-threat to susceptible populations
-
[116] Li, Y., Zhang, Y., Yan, B., Nanotoxicity overview: nano-threat to susceptible populations. Int. J. Mol. Sci. 15:3 (2014), 3671–3697.
-
(2014)
Int. J. Mol. Sci.
, vol.15
, Issue.3
, pp. 3671-3697
-
-
Li, Y.1
Zhang, Y.2
Yan, B.3
-
117
-
-
84883856935
-
Nanotechnology-based drug delivery systems for targeting, imaging and diagnosis of neurodegenerative diseases
-
[117] Pehlivan, S.B., Nanotechnology-based drug delivery systems for targeting, imaging and diagnosis of neurodegenerative diseases. Pharm. Res. 30 (2013), 2499–2511.
-
(2013)
Pharm. Res.
, vol.30
, pp. 2499-2511
-
-
Pehlivan, S.B.1
|